Skip to content
Screener

SELLAS Life Sciences Group, Inc. SLS Retained Earnings

Retained Earnings at other companies

Pfizer logo
PfizerPFE
$117.24B-2.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$1.55B-18.6%
AbbVie logo
AbbVieABBV
-$17.87B-87.6%
Immunome logo
ImmunomeIMNM
-$782M-40.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$1.7B-37.0%
CTO
Citius Oncology, Inc.CTOR
-$96.18M-79.2%

Other financials

Income statement

See full
Revenue-—
Gross profit-—
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$2.3B+1,350%
Enterprise value$2.19B+1,537%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%—

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0×0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001390478-26-000008
Line itemMarch 31, 2026December 31, 2025
Total liabilities6,7657,474
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value; 350,000,000 shares authorized, 181,332,574 and 153,103,459 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively1815
Additional paid-in capital390,789345,844
Accumulated deficit(283,395)(274,988)
Total stockholders’ equity107,41270,871
Total liabilities and stockholders’ equity$114,177$78,345

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is SELLAS Life Sciences Group, Inc.'s retained earnings?
SELLAS Life Sciences Group, Inc. (SLS) reported retained earnings of -$283.4M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s retained earnings changed year-over-year?
SELLAS Life Sciences Group, Inc.'s retained earnings decreased by 11.6% year-over-year, from -$253.94M to -$283.4M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s retained earnings?
Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s retained earnings has grown at a 18.5% compound annual growth rate (CAGR), from -$117.9M to -$274.99M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about SELLAS Life Sciences Group, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude